Cirrhosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*The risks and costs of prophylactic transfusions may exceed the benefit. | *The risks and costs of prophylactic transfusions may exceed the benefit. | ||
* [[Intravenous]] [[ciprofloxacin]] followed by oral administration of this drug was found to be more cost-effective compared to intravenous ceftazidime in a randomized trial in patients who had not received [[quinolone]] prophylaxis. | * [[Intravenous]] [[ciprofloxacin]] followed by oral administration of this drug was found to be more cost-effective compared to intravenous ceftazidime in a randomized trial in patients who had not received [[quinolone]] prophylaxis. | ||
* Selective intestinal decontamination with [[norfloxacin]] or [[trimethoprim/sulfamethoxazole]] in patients with prior [[spontaneous bacterial peritonitis]] (SBP) or low-[[protein]] ascitic fluid does appear to be cost-effective | * Selective intestinal decontamination with [[norfloxacin]] or [[trimethoprim/sulfamethoxazole]] in patients with prior [[spontaneous bacterial peritonitis]] (SBP) or low-[[protein]] ascitic fluid does appear to be cost-effective. | ||
===Role of [[Transjugular intrahepatic portosystemic shunt|TIPS]] vs distal splenorenal shunt in the management of portal hypertension=== | |||
==Reference== | ==Reference== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 16:30, 6 September 2012
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Cirrhosis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Cirrhosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
According to a report from The National Center for Health Statistics, Cirrhosis and chronic liver disease accounted for more than 25,000 deaths and 373,000 hospital discharges in the United States in 1998.
Cost-effectiveness of Therapy
Management of adult patients with ascites due to cirrhosis
- Abdominal paracentesis with appropriate ascitic fluid analysis is probably the most rapid and cost-effective method of diagnosing the cause of ascites.
- The risks and costs of prophylactic transfusions may exceed the benefit.
- Intravenous ciprofloxacin followed by oral administration of this drug was found to be more cost-effective compared to intravenous ceftazidime in a randomized trial in patients who had not received quinolone prophylaxis.
- Selective intestinal decontamination with norfloxacin or trimethoprim/sulfamethoxazole in patients with prior spontaneous bacterial peritonitis (SBP) or low-protein ascitic fluid does appear to be cost-effective.